Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP, Head of Discovery Chem | July 02, 2021 | July 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 02, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,933 |
Reported balance
After 2021-07-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-02 · Grant · Acquired 7,853 · Balance 101,933 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | Direct | 98,980 |
Reported balance
After 2021-07-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-07-02 · Tax withholding · Disposed 2,953 · Balance 98,980 F2: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. |
| Common StockSEC Table I · non-derivative | Direct | 98,575 |
Reported balance
After 2021-07-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-07-06 · Tax withholding · Disposed 405 · Balance 98,575 F2: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F3: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 58,773 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.58 · Expires 2031-07-01 | Direct | 15,054 |
Reported balance
After 2021-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-02 · Grant · Acquired 15,054 · Balance 15,054 F4: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock.
F3: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 58,773 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.
F4: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2019 Filed Jul 3, 2019 18:58 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,428 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040952 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 16,428 shares Expires 2029-07-01 F4 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:58 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 619 | $85.01 | $52,621.19 |
DisclosureSEC source: 0001209191-19-040952 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,351 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 16,219 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 18:58 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 6,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040952 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,970 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 5,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011309 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,798 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 14, 2019. The performance shares vest 25% annually over four years from the grant date of July 2, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2018 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 150% of the number of performance shares awarded, and the performance criteria was achieved at the 83% level. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units that have not vested as of February 14, 2019. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,354 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-19-004819 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,354 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:04 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 15,354 | $77.61 | $1,191,623.94 |
DisclosureSEC source: 0001209191-19-004819 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,409 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $76.43 to $78.56. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · balance_after: This includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 15,354 | $17.79 | $273,147.66 |
DisclosureSEC source: 0001209191-19-004819 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · derivative · entry 5 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,354 Underlying: Common Stock · 10,000 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 808 | $74.21 | $59,961.68 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,409 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: This includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,000 | $75.00 | $750,000.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,217 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 10,000 | $17.79 | $177,900.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:46 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · derivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:22 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 430 | $70.19 | $30,181.70 |
DisclosureSEC source: 0001209191-18-043120 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,217 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 20:22 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 273 | $68.28 | $18,640.44 |
DisclosureSEC source: 0001209191-18-041610 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,647 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:22 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041610 · doc4.xml · derivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2028-07-01 F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:29 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,026 | $86.03 | $88,266.78 |
DisclosureSEC source: 0001209191-18-012427 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,584 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 10,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 21,167 | $0.00 Strike: $95.34 | $0.00 |
DisclosureSEC source: 0001209191-18-005410 · doc4.xml · derivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,167 Underlying: Common Stock · 21,167 shares Expires 2028-01-23 F2 · derivative.exercise_date: Beginning January 24, 2018, options become exercisable in full on January 24, 2022. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:52 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,128 | $0.00 Strike: $94.63 | $0.00 |
DisclosureSEC source: 0001209191-18-005410 · doc4.xml · derivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2028-01-22 F1 · derivative.exercise_date: Beginning January 23, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on July 5, 2018 and the remainder vesting monthly over three years. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:39 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 674 | $123.15 | $83,003.10 |
DisclosureSEC source: 0001209191-17-052994 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,610 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 13,316 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:54 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,128 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044416 · doc4.xml · derivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,128 Underlying: Common Stock · 12,128 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:54 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 3,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044416 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,284 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Yao's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:33 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 4,413 | $125.00 | $551,625.00 |
DisclosureSEC source: 0001209191-17-030952 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,767 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:43 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 788 | $121.95 | $96,096.60 |
DisclosureSEC source: 0001209191-17-015317 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,843 F3 · shares: Represents shares withheld to satisfy tax withholding obligations with respect to vested performance shares. F2 · balance_after: Includes an aggregate of 21,380 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 14, 2017 Filed Feb 28, 2017 21:43 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-015317 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,631 F1 · shares: Represents shares acquired upon vesting of performance shares. Each performance share represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical and revenue milestones as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded. Performance share milestones were achieved at the 100% level. F2 · balance_after: Includes an aggregate of 21,380 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:59 UTC | INCYTE CORP INCY · Entity 3182 | GrantIncentive Stock Option (right to buy) · Derivative | 879 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004563 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879 Underlying: Common Stock · 879 shares Expires 2027-01-16 F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:59 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,986 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004563 · doc4.xml · derivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,986 Underlying: Common Stock · 17,986 shares Expires 2027-01-16 F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:59 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,091 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004563 · doc4.xml · derivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,091 Underlying: Common Stock · 19,091 shares Expires 2027-01-16 F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.